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ABSTRACT 
Glioblastomas are the most common and devastating primary tumors of the central nervous 
system, with high proliferative capacity, aggressive invasion, and resistance to conventional 
therapies. Differentiation therapy has emerged as a promising candidate modality. Here we 
show that the traditional phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002 is capable 
of inducing differentiation of C6 glioblastoma cells characterized by morphological changes 
to astrocytic phenotype, increase in differentiation marker protein glial fibrillary acidic pro-
tein and inhibition of proliferation. Small interfering RNA against glycogen synthase kinase-
3β (GSK-3β) suppresses the induced-differentiation and invasiveness in C6 cells. LY294002 
also inhibits MMP-9 expression and invasion of C6 cells, assembling the role of metallopro-
tease (MMP) inhibitor AG3340. Taken together, these findings suggest differentiation-
inducing and invasion-inhibitory effectiveness of LY294002 in glioblastomas, most likely in-
volving inhibition of GSK-3β and MMP respectively. 
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INTRODUCTION 
Glioblastoma is the most frequent and 
most malignant human brain tumor  (DeAn-
gelis, 2001). Similar to many malignant tu-
mors, glioblastoma has a characteristically 
high proliferation index; however, the most 
devastating and thus far therapeutically in-
tractable aspect of its biology is its highly 
invasive nature, which prevents complete 
tumor resection and causes significant neu-
rological morbidity and, ultimately, mortali-
ty (Giese et al., 2003; Keles and Berger, 
2004). The prognosis of these tumors is ex-
tremely poor, and the majority of patients 
die within 9 to 12 months after diagnosis 
(Maher et al., 2001; Stupp et al., 2007). 
Therefore，the treatment of glioblastoma 
requires novel strategies that take the pres-
ently incurable nature of the disease into 
consideration.  
The process of neoplastic cell growth 
represents a dysfunctional balance between 
control of cell proliferation and terminal dif-
ferentiation (Scott, 1997). The aberrantly 
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differentiated cells show abnormal growth 
characteristics and distinct invasive and 
metastatic properties (Sell, 2004). Treating 
malignant tumor through the induction of 
cell differentiation has been successful for 
the treatment of acute promyelocytic leuke-
mia (Huang et al., 1988), showing promise 
in treating malignant tumors (Leszczyniecka 
et al., 2001).  
LY294002 [2-(4-morpholinyl)-8-phenyl-
4H-1-benzopyran-4-one] is a flavonoid-
based synthetic compound that inhibits 
phosphatidylinositol 3 kinase (PI3K), com-
peting for the occupancy of the ATP pocket 
of the catalytic subunit of PI3K (Vlahos et 
al., 1994). LY294002 has been shown to ex-
ert antitumorigenic effect in vivo and in vitro 
by induction of apoptosis and cell growth 
arrest (Poh and Pervaiz, 2005; Cheng et al., 
2008). Moreover, tumor cell invasion and 
migration could be significantly attenuated 
by LY294002 treatment in several tumor 
models (Matsushita et al., 2007; Liu et al., 
2008; Meng et al., 2009). Until now, how-
ever, little is known about its possible role 
involved in the process of cancer cell differ-
entiation. 
In the present study, we demonstrated 
that LY294002 induces cellular differentia-
tion and inhibits invasion of malignant glio-
blastoma cells. GSK-3β suppression via 
siRNA-triggered gene silencing inhibits the 
induced differentiation; metalloprotease 
(MMP) inhibitor AG3340 decreased the in-
hibited invasiveness, indicating that differ-
entiation and invasion-inhibition triggered 
by LY294002 is affected through GSK-3β 
and MMP respectively. It also provides nov-
el evidence that GSK-3β is a potential target 
in the differentiation therapy of human glio-
blastoma multiforme. 
 
MATERIALS AND METHODS 
Cell culture and drug treatment 
C6 cells were obtained from the Ameri-
can Type Culture Collection (Manassas, 
VA) and maintained in Dulbecco’s modified 
Eagle’s Medium (DMEM, Invitrogen, Grand 
Island, NY) supplemented with 10 % FBS 
(Invitrogen) in a humidified atmosphere of 
5 % CO2 at 37 °C. Cell differentiation was 
induced with 20 μM LY294002 (Sigma, St. 
Louis, MO) in DMEM containing 1 % FBS. 
Control was treated with an equivalent vol-
ume of DMEM containing 0.1 % DMSO. 
 
Morphological evaluation 
The morphologies of cells were studied 
using an Olympus (Melville, NY) IX71 in-
verted microscope along with a Olympus DP 
Controller software.  
 
Proliferation assay 
For cell proliferation assay, a 5-bromo-
2-deoxyuridine (BrdU) labeling and detec-
tion kit (Roche Diagnostics, Mannheim, 
Germany) was used according to the manu-
facturer’s instructions. Cells seeded in 96-
well plates at 2 × 103 cells/well with tripli-
cate wells for each condition were labeled 
with BrdU for 4 h, then anti-BrdU-POD Fab 
fragments and substrate were added in se-
quence. The OD was determined at 405 nm 
using an EXL800 microimmunoanalyzer 
(Bio-Tek Instruments, Burlington, VT). 
 
Cell cycle analysis 
A flow cytometry analysis of DNA con-
tent of cells was performed to assess the 
cell-cycle phase redistributions as described 
(Roz et al., 2002). In brief, the cells were 
collected by trypsinization, washed in PBS 
and fixed in 70 % ethanol for 30 min at 4 ℃. 
After washing with PBS, cells were incubat-
ed with the DNA-binding dye propidium 
iodide (PI, 50 mg/ml), RNase (4 Ku/ml), 
NaF (0.3 mg/ml) and sodium citrate 
(1 mg/ml) for 30 min at 37 °C in the dark. 
Finally, red fluorescence from 488 mm la-
ser-excited PI in every cells was analyzed by 
EPICS ALTRA flow cytometer (Beckman 
Coulter, Fullerton, CA) using a peak fluo-
rescence gate to discriminate aggregates. 
The percentage of cells in G0/G1, S and 
G2/M was determined from DNA content 
histograms by Multicycle for windows 
(Phoenix Flow Systems, San Diego, CA). 
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Cell invasion assay 
Cell invasion was assayed in a cell cul-
ture chamber (BD Biosciences, Bedford, 
MA) with 8 μm pore size polycarbonate 
membrane filters. The filters were pre-
coated with 50 μl Matrigel (1.25 mg/ml). 
Cells were harvested and seeded in upper 
chambers at a density of 1×104 cells/well 
with DMEM containing 1 % FBS. Mean-
while, 0.6 ml complete medium with 10 % 
FBS and 20 μM LY294002 was placed in 
bottom chambers. At the same time, moreo-
ver, equal cells were plated to 96-well plates 
for cell number assay (MTT). The chamber 
was incubated at 37 °C for 24 h and then the 
Matrigel was removed with a cotton bud. 
The invaded cells were fixed with 4 % para-
form, stained with hematoxylin, photo-
graphed and counted. The invasiveness of 
C6 cells was determined by the percentage-
of-invasion score (invaded cell number / to-
tal cell number × 100 %). 
 
Western Blot analysis 
After lysis of cells and measurement of 
protein concentration, the cells were dis-
solved in SDS sample buffer [62.5 mM Tris-
HCl, PH 6.8, 2 % SDS, 10 % glycerol, 
50 mM DTT, and 0.1 % bromophenol blue]. 
Equal amount of proteins were analyzed by 
SDS-PAGE on 12 % poly-acrylamide gels. 
Proteins were electroblotted on a nitrocellu-
lose membrane.  Membranes were incubated 
in 5% nonfat dry milk in TBST (Tris-
buffered saline, 0.05 % Tween-20) and then 
overnight at 4 °C with antibodies against 
GFAP, p-Akt, Akt, p-GSK-3β, GSK-3β 
(1:1000, Cell Signaling Technology, Bever-
ly，MA), PCNA (1:10000, Cell Signaling 
Technology) MMP-2, MMP-9 (1:500, Santa 
Cruz Biotechnology, Santa Cruz, CA) and 
GAPDH (1:2000, Cell Signaling Technolo-
gy) respectively. After incubation with 
horseradish peroxidase-labelled secondary 
antibody (1:1000, Cell Signaling Technolo-
gy), visualization was achieved with en-
hanced chemiluminescence (Pierce, Rock-
ford, USA) using a GeneGnome chemilumi-
nescence imaging and analysis system 
(Syngene Bio Imaging, Cambridge, UK).  
 
RNA silencing of GSK-3β 
Rat GSK-3β siRNA and scrambled siR-
NA (control) were purchased from Invitro-
gen. C6 cells with 30~50 % confluence were 
transfected using Lipofectamine 2000 rea-
gent (Invitrogen) following the manufactur-
er’s protocol. Inhibition of GSK-3β protein 
expression was assessed by immunoblot 
analysis 48 h after transfection. 36 h post-
transfection, cells were incubated with 
LY294002 for additional 48 h for further 
analysis. 
 
Statistical analysis 
Data are presented as mean ± standard 
deviation (SD) of three separate experi-
ments. Statistical significance was deter-
mined by Student’s t-test.  A result with a p-
value of less than 0.05 is considered statisti-
cally significant. 
 
RESULTS 
LY294002 induces differentiation of C6 
glioblastoma cells 
Differentiation of rat C6 glioblastoma 
cells towards astrocyte type is characterized 
by morphological transformation from flat 
polygonal appearance to spindle-shape with 
processes (Li et al., 2007). Microscopic ob-
servation of C6 glioblastoma cells treated 
with 20 μM in our study revealed major al-
terations in their morphology. Unlike the 
mainly polygonal morphology of control, 
the shape of LY294002 treated C6 cells was 
similar to that of mature astrocytes, with 
smaller round cell bodies and much longer, 
fine, tapering processes (Figure 1A). This 
indicates that LY294002 has the ability to 
induce glioblastoma cells differentiating into 
maturation process of astrocytes.   
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Figure 1: LY294002 induces differentiation of C6 glioblastoma cells. (A) Morphological transformation 
induced by 20 μM LY294002 for 48 h (Scale bar: 50 μM). (B) Immunoblot of GFAP and PCNA expres-
sion. Cells were treated with 0, 5, 10 and 20 μM LY294002 for 48 h. (C) Cell cycle distributions in cells 
treated with 20 μM LY294002 for the time indicated. (D) Proliferating cells determined by measuring 
the amount of BrdU incorporation. Cells were treated with 20 μM LY294002 for the time indicated. Re-
sults are means ± SD (n=3). Statistical differences compared with the controls are given as *p < 0.05 
and **p < 0.01. 
 
 
We further examined the expressions of 
glial fibrillary acid protein (GFAP), a well-
established marker of mature astrocytes 
(Roymans et al., 2001) and PCNA, the relia-
ble marker of proliferating cells (Krishna et 
al., 1994). As indicated in Figure 1B, West-
ern blotting analysis confirmed a significant 
up-regulation of GFAP protein expression in 
LY294002 treated cells compared with the 
controls in a concentration-dependent man-
ner with a maximal induction effect at 
20 μM, while the expression of PCNA was 
notably restrained by LY294002 in a similar 
concentration dependent manner. Flow cy-
tometry analysis also showed that 
LY294002 led to a time-dependent C6 ac-
cumulation in G1 phase. Concomitantly, 
there was a striking decrease in the S frac-
tion (Figure 1C), indicating that a subset of 
cells actually exits from the cell cycle and 
then differentiates. BrdU incorporation as-
say was next used to examine the effect of 
LY294002 on growth of C6 cells (Figure 
1D). Treatment of C6 cells for 48 h with 
20 μM LY294002 caused marked inhibition 
of growth in a time dependent manner. As 
seen in Figure 1D, LY294002 (20 μM) di-
minished the proliferation of C6 cells to 
78.7 % of the controls at 24 h (p < 0.05). 
 
LY294002 inhibits invasion of C6  
glioblastoma cells 
Brain invasion is a biological hallmark 
of glioblastoma that contributes to its ag-
gressiveness. We thus tested whether 
LY294002 may also affect the invasiveness 
of C6 cells. Matrigel invasion analysis con-
firmed that LY294002 led to a remarkable 
reduction of invading cells. As seen in Fig-
ure 2A and B, LY294002 (20 μM) dimin-
ished the invasion ability of the C6 cells to 
52.2 % of the controls at 24 h (p < 0.05). 
Thus, the results indicate that LY294002 can 
regulate the invasion of glioblastoma cells. 
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Figure 2: LY294002 inhibits the invasion of C6 
glioblastoma cells. (A) Matrigel invasion assay of 
C6 cells treated with 20 μM LY294002 after 48 h 
(Scale bar = 50 μM). (B) Statistical analysis of 
three independent experiments. The data are 
mean ± SD (n=3). * p <0.05, ** p <0.01 com-
pared with control.  
 
 
Activation of GSK-3β in glioblastoma cells 
We first confirmed the PI3K-Akt inhibi-
tory activity of LY294002 at concentrations 
used in the current study. Glioblastoma cells 
were treated with 20 μM LY294002 and the 
effect on Akt activation was assessed by 
Western blot analysis. As shown in Figure 3, 
LY294002 treatment effectively inhibited 
Akt phosphorylation following 6 h drug 
treatment.  
To determine whether LY294002 affects 
activity of GSK-3β, the downstream kinase 
of Akt, GSK-3β phosphorylation at the Ser-
9 residue, which represents the inactive form 
of GSK-3β kinase (Cross et al., 1995), was 
determined. As shown in Figure 3, GSK-
3βSer-9 protein level was significantly down-
regulated in C6 cells after 6 h incubation. 
The most robust GSK-3βSer-9 protein reduc-
tion appeared at 6 h treatment and then 
maintain at a low level. Total Akt and total 
GSK-3β remains stable throughout. These 
data revealed that LY294002 inhibits 
PI3K/Akt pathway and activates its down-
stream kinase GSK-3β.  
 
 
Figure 3: Akt inhibition and GSK-3β activation 
induced by LY294002 in C6 glioblastoma cells. 
Immunoblot of p-AktSer473, Akt, p-GSK-3βser9 
and GSK-3β levels in C6 cells treated with 
20 μM LY294002 for the indicated time.  
 
 
GSK-3β gene knockdown inhibits differen-
tiation induced by LY294002 in C6 cells  
To further confirm the role of GSK-3β in 
glioblastoma cell differentiation, we exam-
ined the effects of GSK-3β inhibition. To 
selectively down-regulate expression of 
GSK-3β proteins, we evaluated the effect of 
isoform-specific GSK-3β gene silencing 
mediated by siRNAs. As shown in Figure 
4A, cells transfected with GSK-3β siRNA 
resulted in dramatically knockdown of the 
protein levels compared with those trans-
fected with scrambled control siRNA. In ad-
dition, morphological transformation and 
elevation of GFAP during C6 cell differenti-
ation were blocked by 10 nM GSK-3β spe-
cific siRNA (Figure 4B and 4C). These re-
sults suggest the requisite role of GSK-3β in 
the differentiation of glioblastoma cells and 
suggest that GSK-3β positively regulates the 
differentiation induced by LY294002. 
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Figure 4: Silencing GSK-3β blocks differentia-
tion induced by LY294002 in C6 cells. (A) Im-
munoblot of the GSK-3β protein levels after 
transfection with 10 nM scrambled (Scram) or 
GSK-3β siRNAs (siGSK-3β) for 36 h. (B-C) Mor-
phology (Scale bar = 50 μM). (B) and immuno-
blot of the GFAP and PCNA levels (C) in GSK-
3β knockdown cells subsequently stimulated 
with 20 μM LY294002 for 48 h.  
 
 
GSK-3β gene knockdown inhibits invasion 
of C6 glioblastoma cells 
We further examine the role of GSK-3β 
in glioblastoma invasion. Matrigel-based 
invasion assay indicate that GSK-3β gene 
knockdown obviously suppress the invasion 
of C6 cells (Figure 5A and 5B), indicating 
LY294002 inhibit invasion independent its 
PI3K/Akt inhibition and the following GSK-
3β activation activity.  
 
 
Figure 5: Silencing GSK-3β inhibits the invasion 
of C6 glioblastoma cells. (A) Matrigel invasion 
assay of C6 cells pretreated with 10 nM scram-
bled (Scram) or GSK-3β siRNAs (siGSK-3β) for 
36 h (Scale bar = 50 μM). (B) Statistical analysis 
of three independent experiments. The data are 
mean ± SD (n=3). * p < 0.05, ** p < 0.01 com-
pared with control.  
 
 
MMP inhibitor suppresses differentiation 
of C6 glioblastoma cells 
Cellular invasion requires the participa-
tion of several types of hydrolytic enzyme 
systems, including plasminogen activators 
and the MMP, such as gelatinase (MMP-2 
and MMP-9). MMP-2 and MMP-9 expres-
sion in C6 glioblastoma cells was then as-
sessed by Western blot analysis. As shown 
in Figure 6A, LY294002 treatment markedly 
decreased MMP-9 protein level, while the 
protein level of MMP-2 remained stable. In 
addition, by using AG3340 which specifical-
ly inhibits MMPs, we noted a significant 
reduction in C6 invasion through a Matrigel 
barrier at doses of 100 μM (Figure 6B), 
which had no effect on cell growth (data not 
shown). The invasiveness was reduced more 
than 50 % (p < 0.01) by AG3340 (Figure 
6C). The action of LY294002 on MMP may 
account for its drastic effect on the inhibi-
tion of the invasiveness of glioblastoma 
cells.  
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Figure 6: AG3340 impaired invasion of C6 glio-
blastoma cells. (A) Immunoblots of the MMP-2 
and MMP-9 protein levels of cells treated with 
20 μM LY294002 for 48 h. (B) Matrigel invasion 
assay of C6 cells pretreated with 100 μM 
AG3340 for 24 h (Scale bar = 50 μM). (C) Statis-
tical analysis of three independent experiments 
in panel B. The data are mean ± SD (n=3). * p < 
0.05, ** p < 0.01 compared with control. 
 
 
DISCUSSION 
Rat C6 glioblastoma cells are a rapidly 
proliferating cell line with an undifferentiat-
ed phenotype and oligodendrocytic, astro-
cytic and neuronal properties. It has been 
used as a model to study glial differentia-
tion. GFAP is important in maintaining 
normal morphology and regulating aspects 
of the growth of glioblastoma cells. Synthe-
sis of GFAP seems to be required for the 
formation of stable astrocytic processes 
(Chen and Liem, 1994). An increase in 
GFAP expression in cultured glioma cells 
associated with morphological changes indi-
cates cellular differentiation (Rutka et al., 
1994; Takanaga et al., 2004; Li et al., 2007). 
Here we showed that exposure of C6 glio-
blastoma cells to LY294002 resulted in their 
morphological changes to astrocytic pheno-
type, increase in astrocytic differentiation 
marker protein GFAP and decrease in pro-
liferation, indicating the differentiation-
inducing effectiveness of LY294002.  
The phosphatidylinositol 3-kinase 
(PI3K)-Akt/PKB signaling is a well-charac-
terized pathway involved in the control of 
cell proliferation, apoptosis, angiogenesis 
and oncogenesis (Vivanco and Sawyers, 
2002; Yamaguchi et al., 2006). Deregulated 
activation of this pathway, achieved through 
numerous genetic and epigenetic alterations, 
has been found in many types of cancer in-
cluding glioblastomas (Ramos et al., 2005; 
Tokunaga et al., 2008). LY294002 is a 
commonly used pharmacologic inhibitor of 
PI3K, where it acts on the ATP-binding site 
of the PI3K enzyme, thus selectively inhibit-
ing the PI3K-Akt nexus. Akt is considered 
to be the principal enzyme that phosphory-
lates and inhibits GSK-3 activation at an N-
terminal serine (serine-9 in GSK-3β) (Cross 
et al., 1995). 
GSK-3 regulates diverse processes, in-
cluding metabolism, cell fate specification, 
cell division, and cell death (Frame and Co-
hen, 2001; Doble and Woodgett, 2003). Two 
closely related isoforms, GSK-3α and GSK-
3β, function in multiple pathways, including 
Wnt, notch, tyrosine kinase, and G-protein 
coupled receptor signaling. The role of 
GSK-3 in cancer cell differentiation is bare-
ly studied, and current data are conflicting. 
For example, it has been suggested Microtu-
bule-associated protein 1B (MAP1B) phos-
phorylation by a novel isoform of GSK-3 is 
induced during PC12 cell differentiation 
(Goold and Gordon-Weeks, 2001). On the 
other hand, GSK-3β is accumulated in poor-
ly differentiated pancreatic adenocarcinoma 
and inhibition of GSK-3β arrests pancreatic 
tumor growth (Ougolkov et al., 2005). Little 
is known regarding the function and status 
of GSK-3 in glioblastoma cells. Our data, 
suggesting that GSK-3β inhibition can block 
glioblastoma cell differentiation, suggest 
that GSK-3β is a central point of regulation 
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for the cellular differentiation of glioblasto-
ma cells. Identification of pro-differentiation 
molecules that downstream of GSK-3β is a 
major part of our ongoing studies in this ar-
ea. 
A major characteristic of glioblastoma is 
the propensity to invade and become re-
sistant to chemotherapeutic agents. Glioblas-
toma cells often infiltrate beyond any obvi-
ously defined tumor margin and contribute 
to the high incidence of recurrence (Yana-
mandra et al., 2004). The invading cells are 
extremely resistant to radiation and chemo-
therapy, and currently there are no anti-
invasive therapies available (Lefranc et al., 
2005). Because local invasion of neoplastic 
cells into the surrounding brain is perhaps 
the most important aspect of the biology of 
glioblastomas precluding successful treat-
ment, pharmacological inhibition of glio-
blastoma cell migration and brain invasion is 
considered as a promising strategy for the 
treatment of glioblastoma (Giese et al., 
2003; Kislin et al., 2009; Zhang et al., 
2009). The Matrigel invasion assay con-
firmed that LY294002 led to a remarkable 
reduction of invading cells in the C6 glio-
blastoma cells. 
The acquisition of invasive potential 
through proteinase expression is an essential 
event in tumor progression. MMPs are a 
family of regulating cell invasion processes 
through their proteolytic function in normal 
and pathological states. Among proteinases, 
MMP-2 and MMP-9 have been shown to be 
increased in glioblastoma and are thought to 
play a key role in facilitating the invasion of 
glioblastoma cells through brain parenchy-
ma (Rao et al., 1993; Forsyth et al., 1998). 
Our results reveal that the expression of 
MMP-9 was significantly decreased in the 
glioblastoma cells while MMP-2 was invari-
able. MMP inhibitor AG3340 resembled the 
invasion-inhibition role of LY294002, while 
GSK-3β siRNA could not attenuate the in-
hibitory activity of LY294002. These results 
indicate that LY294002 suppresses glioblas-
toma cell invasion and migration at least in 
part involving down-regulation of MMP-2, 
independent of its PI3K-Akt inhibitory and 
GSK-3β activating activity. These data pro-
vide a novel explanation for the anticancer 
properties of LY294002 in glioblastoma.  
In summary, our present data show that 
treatment of C6 glioblastoma cells with 
LY294002 resulted in growth inhibition, 
mature morphological changes, and in-
creased GFAP expression indicative of cel-
lular differentiation. Intervention in GSK-3β 
function by siRNA abolished the effective-
ness of LY294002 in glioblastoma cells. 
LY294002 also potentially inhibited inva-
siveness of glioblastoma cells as the MMP 
inhibitor. In conclusion, our work suggests 
that LY294002 may serve as a novel anti-
glioblastoma agent, since it is implicated in 
many areas of tumor progression, including 
cell growth, cell differentiation and inva-
sion, at least in part by targeting GSK-3β 
and MMP-9.  
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